Information Provided By: 
Fly News Breaks for February 26, 2020
GBT
Feb 26, 2020 | 20:36 EDT
Piper Sandler analyst Danielle Brill keeps her Overweight rating and $120 price target on Global Blood Therapeutics after its Q4 results. The analyst notes that the management's commentary suggests that Oxbryta launch is going well with $2.1M in contributed revenue, even though it was only available for a couple of weeks in December. Brill adds that she continues to view the demand for Oxbryta as high, and she is not concerned with the management holding off on providing hard launch metrics.
News For GBT From the Last 2 Days
There are no results for your query GBT
